Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values
- PMID: 28416539
- PMCID: PMC5444165
- DOI: 10.1128/AAC.00485-17
Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values
Abstract
Candida auris is an emerging multidrug-resistant yeast. So far, all but two susceptibility testing studies have examined ≤50 isolates, mostly with the CLSI method. We investigated CLSI and EUCAST MICs for 123 C. auris isolates and eight antifungals and evaluated various methods for epidemiological cutoff (ECOFF) determinations. MICs (in milligrams per liter) were determined using CLSI method M27-A3, and the EUCAST E.Def 7.3. ANOVA analysis of variance with Bonferroni's multiple-comparison test and Pearson analysis were used on log2 MICs (significance at P values of <0.05). The percent agreement (within ±0 to ±2 2-fold dilutions) between the methods was calculated. ECOFFs were determined visually, statistically (using the ECOFF Finder program and MicDat1.23 software with 95% to 99% endpoints), and via the derivatization method (dECOFFs). The CLSI and EUCAST MIC distributions were wide, with several peaks for all compounds except amphotericin B, suggesting possible acquired resistance. Modal MIC, geometric MIC, MIC50, and MIC90 values were ≤1 2-fold dilutions apart, and no significant differences were found. The quantitative agreement was best for amphotericin B (80%/97% within ±1/±2 dilutions) and lowest for isavuconazole and anidulafungin (58%/76% to 75% within ±1/±2 dilutions). We found that 90.2%/100% of the isolates were amphotericin B susceptible based on CLSI/EUCAST methods, respectively (i.e., with MICs of ≤1 mg/liter), and 100%/97.6% were fluconazole nonsusceptible by CLSI/EUCAST (MICs > 2). The ECOFFs (in milligrams per liter) were similar across the three different methods for itraconazole (ranges for CLSI/EUCAST, 0.25 to 0.5/0.5 to 1), posaconazole (0.125/0.125 to 0.25), amphotericin B (0.25 to 0.5/1 to 2), micafungin (0.25 to 0.5), and anidulafungin (0.25 to 0.5/0.25 to 1). In contrast, the estimated ECOFFs were dependent on the method applied for voriconazole (1 to 32) and isavuconazole (0.125 to 4). CLSI and EUCAST MICs were remarkably similar and confirmed uniform fluconazole resistance and variable acquired resistance to the other agents.
Keywords: Candida auris; ECOFF; MIC; amphotericin B; antifungal susceptibility testing; azoles; echinocandins; in vitro.
Copyright © 2017 American Society for Microbiology.
Figures

Similar articles
-
In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents.Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02136-19. doi: 10.1128/AAC.02136-19. Print 2020 Feb 21. Antimicrob Agents Chemother. 2020. PMID: 31844005 Free PMC article.
-
APX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method.Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01225-18. doi: 10.1128/AAC.01225-18. Print 2018 Oct. Antimicrob Agents Chemother. 2018. PMID: 30104264 Free PMC article.
-
Manogepix (APX001A) In Vitro Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs.Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00656-20. doi: 10.1128/AAC.00656-20. Print 2020 Sep 21. Antimicrob Agents Chemother. 2020. PMID: 32660998 Free PMC article.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
How to interpret MICs of amphotericin B, echinocandins and flucytosine against Candida auris (Candidozyma auris) according to the newly established European Committee for Antimicrobial Susceptibility Testing (EUCAST) breakpoints.Clin Microbiol Infect. 2025 Jul 11:S1198-743X(25)00340-4. doi: 10.1016/j.cmi.2025.07.002. Online ahead of print. Clin Microbiol Infect. 2025. PMID: 40651666 Review.
Cited by
-
PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris.CPT Pharmacometrics Syst Pharmacol. 2023 Jun;12(6):770-782. doi: 10.1002/psp4.12949. Epub 2023 Mar 13. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36915233 Free PMC article.
-
Successful treatment of C. auris shunt infection with intraventricular caspofungin.Med Mycol Case Rep. 2018 Aug 11;22:35-37. doi: 10.1016/j.mmcr.2018.08.005. eCollection 2018 Dec. Med Mycol Case Rep. 2018. PMID: 30140604 Free PMC article.
-
Rapid Detection of ERG11-Associated Azole Resistance and FKS-Associated Echinocandin Resistance in Candida auris.Antimicrob Agents Chemother. 2018 Dec 21;63(1):e01811-18. doi: 10.1128/AAC.01811-18. Print 2019 Jan. Antimicrob Agents Chemother. 2018. PMID: 30397051 Free PMC article.
-
Candida auris, what do paediatricians need to know?Arch Dis Child. 2018 Sep;103(9):891-894. doi: 10.1136/archdischild-2017-313960. Epub 2018 Mar 15. Arch Dis Child. 2018. PMID: 29545411 Free PMC article. Review.
-
Candida auris Infection Leading to Nosocomial Transmission, Israel, 2017.Emerg Infect Dis. 2018 Apr;24(4):801-804. doi: 10.3201/eid2404.171715. Emerg Infect Dis. 2018. PMID: 29553329 Free PMC article.
References
-
- Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, Colombo AL, Calvo B, Cuomo CA, Desjardins CA, Berkow EL, Castanheira M, Magobo RE, Jabeen K, Asghar RJ, Meis JF, Jackson B, Chiller T, Litvintseva AP. 2017. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis 64:134–140. doi:10.1093/cid/ciw691. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources